JP6893173B2 - Ｃｎｓ障害を処置するための組成物および方法 - Google Patents
Ｃｎｓ障害を処置するための組成物および方法 Download PDFInfo
- Publication number
- JP6893173B2 JP6893173B2 JP2017528154A JP2017528154A JP6893173B2 JP 6893173 B2 JP6893173 B2 JP 6893173B2 JP 2017528154 A JP2017528154 A JP 2017528154A JP 2017528154 A JP2017528154 A JP 2017528154A JP 6893173 B2 JP6893173 B2 JP 6893173B2
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- compound
- alkyl
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 CC(CC1)([C@@](CC2)C(CC3)C1[C@@](CC1)[C@@]3C[C@@]1(O)I)[C@]2C(C1(CCC*=C)*CC1)=O Chemical compound CC(CC1)([C@@](CC2)C(CC3)C1[C@@](CC1)[C@@]3C[C@@]1(O)I)[C@]2C(C1(CCC*=C)*CC1)=O 0.000 description 24
- IMRWILPUOVGIMU-UHFFFAOYSA-N Brc1ncccc1 Chemical compound Brc1ncccc1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 1
- KZAQVQJKRXZYKK-MBKVACPOSA-N CC(C)([C@@H](CC1)[C@@](C)(CC2)[C@]1(C)[C@H](CC1)[C@@]2(C)[C@@H](CC2)[C@H]1C[C@]2(C)O)c1cnccc1 Chemical compound CC(C)([C@@H](CC1)[C@@](C)(CC2)[C@]1(C)[C@H](CC1)[C@@]2(C)[C@@H](CC2)[C@H]1C[C@]2(C)O)c1cnccc1 KZAQVQJKRXZYKK-MBKVACPOSA-N 0.000 description 1
- LFPPIWMEAAXRLW-UHFFFAOYSA-N CC(C)CC(C)N(C)OC Chemical compound CC(C)CC(C)N(C)OC LFPPIWMEAAXRLW-UHFFFAOYSA-N 0.000 description 1
- WPJPSYHNDMBZKW-ZYEQNNROSA-N CC(Oc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@]2(C)O)=N)(F)F Chemical compound CC(Oc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1C(CC1)[C@H]2[C@@](C)(CC2)[C@H]1C[C@]2(C)O)=N)(F)F WPJPSYHNDMBZKW-ZYEQNNROSA-N 0.000 description 1
- DBTCVTWICOWTAO-LGOYVUFDSA-N CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@]2(C)[C@H]1CC(C)(C)CC2)=O Chemical compound CCc(cc1)ccc1C([C@@H](CC1)[C@@](C)(CC2)[C@@H]1[C@H](CC1)[C@H]2[C@]2(C)[C@H]1CC(C)(C)CC2)=O DBTCVTWICOWTAO-LGOYVUFDSA-N 0.000 description 1
- XYZWMVYYUIMRIZ-UHFFFAOYSA-N CN(C)c(cc1)ccc1Br Chemical compound CN(C)c(cc1)ccc1Br XYZWMVYYUIMRIZ-UHFFFAOYSA-N 0.000 description 1
- NCBZRJODKRCREW-UHFFFAOYSA-N COc1cccc(N)c1 Chemical compound COc1cccc(N)c1 NCBZRJODKRCREW-UHFFFAOYSA-N 0.000 description 1
- ITPWADYSOCLNTA-ILSCHMRGSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1c[s]cc1)=O Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1c[s]cc1)=O ITPWADYSOCLNTA-ILSCHMRGSA-N 0.000 description 1
- PSLHTBSZNHOGDF-JYQNWREZSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ccc(C)cc1)=N PSLHTBSZNHOGDF-JYQNWREZSA-N 0.000 description 1
- VJYRHFJHIQBMRJ-BLGFVBJKSA-N C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@H](CC2)[C@@]1(C)[C@H]2C(c1nc(cccc2)c2[s]1)=O Chemical compound C[C@@H](CC1)C[C@@H](CC2)[C@H]1[C@@H](CC1)[C@]2(C)[C@H](CC2)[C@@]1(C)[C@H]2C(c1nc(cccc2)c2[s]1)=O VJYRHFJHIQBMRJ-BLGFVBJKSA-N 0.000 description 1
- KAULIZSEWDCUCV-BHDSADDHSA-N C[C@@H](CC1)C[C@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ncccc1)=N Chemical compound C[C@@H](CC1)C[C@H](CC2)[C@H]1[C@@H](CC1)[C@@H]2[C@H](CC2)[C@@]1(C)[C@H]2C(c1ncccc1)=N KAULIZSEWDCUCV-BHDSADDHSA-N 0.000 description 1
- WFCVTFUINOLPLV-OVVBHJHBSA-N C[C@@H](CC[C@]1(C)[C@@H](CC[C@]2(C)[C@H](CC3)C(c(cc4)ccc4SC)=N)[C@@](C)(CC4)[C@@]23N)C[C@]14N Chemical compound C[C@@H](CC[C@]1(C)[C@@H](CC[C@]2(C)[C@H](CC3)C(c(cc4)ccc4SC)=N)[C@@](C)(CC4)[C@@]23N)C[C@]14N WFCVTFUINOLPLV-OVVBHJHBSA-N 0.000 description 1
- JDJYBSSMKXYWBA-ROEXDCMRSA-N C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O Chemical compound C[C@H](CC1)[C@](C)(CC[C@@H](CCC2)[C@@H](CC3)[C@@H]2C[C@]3(C)O)[C@H]1C(c(cc1)ccc1OC)=O JDJYBSSMKXYWBA-ROEXDCMRSA-N 0.000 description 1
- YJGOWFOYWPTEJL-QCJJQSFCSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(C)O)[C@H]2C(c1ccccc1F)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)C3C[C@]1(C)O)[C@H]2C(c1ccccc1F)=O YJGOWFOYWPTEJL-QCJJQSFCSA-N 0.000 description 1
- SNMFIDPVGVJPFS-DZCPYTMKSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cccc1)c1OC)=O SNMFIDPVGVJPFS-DZCPYTMKSA-N 0.000 description 1
- XXNBWGJEPGPCSR-VEMLKXGYSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)C#N)[C@H]2C(c(cc1)ccc1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)C#N)[C@H]2C(c(cc1)ccc1-c1ccccc1)=O XXNBWGJEPGPCSR-VEMLKXGYSA-N 0.000 description 1
- BOBXFKPVTXBFDX-XKKDOOBNSA-N C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] Chemical compound C[C@](CC1)([C@@H](CC2)C(CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cnc[nH]1)=[U] BOBXFKPVTXBFDX-XKKDOOBNSA-N 0.000 description 1
- AFOVZRJRFJJSCN-QTLXGVTLSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)C2C(c(cccc1)c1-c1ccccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@@H]3C[C@]1(C)O)C2C(c(cccc1)c1-c1ccccc1)=O AFOVZRJRFJJSCN-QTLXGVTLSA-N 0.000 description 1
- FYJYRINIHYGALP-GXPHRRQYSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C1=C(C)CCS1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1C(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(C1=C(C)CCS1)=O FYJYRINIHYGALP-GXPHRRQYSA-N 0.000 description 1
- VYWDCPPMWFIJCU-WAHCFVBASA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H](CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1c(C)cccc1)=O VYWDCPPMWFIJCU-WAHCFVBASA-N 0.000 description 1
- PFVILKBBBIITMG-ROIBLFINSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cc(OC)ccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@H]1[C@H]3CC(C)(C)CC1)[C@H]2C(c1cc(OC)ccc1)=O PFVILKBBBIITMG-ROIBLFINSA-N 0.000 description 1
- YDUKUYRDNOIQBA-LSBZSBGNSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@@H]3C[C@]1(C)O)[C@H]2C(c(cc1)ccc1Cl)=O YDUKUYRDNOIQBA-LSBZSBGNSA-N 0.000 description 1
- WWZHJUNHNDBLRT-JEJYNDPUSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)C2C(c1c(C)cccc1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)C2C(c1c(C)cccc1)=O WWZHJUNHNDBLRT-JEJYNDPUSA-N 0.000 description 1
- UXTNTNONGLSRPS-RGYBDQPCSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O UXTNTNONGLSRPS-RGYBDQPCSA-N 0.000 description 1
- IOSGZVVLXFCLDP-SCNDPVEVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC1)[C@H]3C[C@]1(C)O)[C@H]2C(c1cccc([I]=C)c1)=O IOSGZVVLXFCLDP-SCNDPVEVSA-N 0.000 description 1
- LEOLRQXBZFHWNP-XIGAYJBWSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@@](C)(CC[C@](C)(C1)O)[C@]31N)[C@H]2C(c1ccc(C)cc1)=C LEOLRQXBZFHWNP-XIGAYJBWSA-N 0.000 description 1
- FBNRZEDRVUANJQ-RLZHEZGZSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@]1(C)[C@@H]3CC(C)(C)CC1)[C@H]2C(C)=N Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC3)[C@H]1[C@]1(C)[C@@H]3CC(C)(C)CC1)[C@H]2C(C)=N FBNRZEDRVUANJQ-RLZHEZGZSA-N 0.000 description 1
- PRAJXDJPZHMACZ-LUUFTWKVSA-N C[C@](CC1)([C@@H](CC2)[C@H](CC[C@@]3(C[C@@](C)(CC4)O)N)[C@H]1[C@]34N)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O Chemical compound C[C@](CC1)([C@@H](CC2)[C@H](CC[C@@]3(C[C@@](C)(CC4)O)N)[C@H]1[C@]34N)[C@H]2C(c(cc1)cc(cc2)c1cc2OC)=O PRAJXDJPZHMACZ-LUUFTWKVSA-N 0.000 description 1
- QVSKBEIYSCNDSZ-VUXXRCJTSA-N C[C@](CC1)([C@H](CC[C@@](C2)(C3(C)CC[C@@]2(C)O)C=C)[C@@]3(CC2)N)[C@@]2(C)[C@H]1C(O)=O Chemical compound C[C@](CC1)([C@H](CC[C@@](C2)(C3(C)CC[C@@]2(C)O)C=C)[C@@]3(CC2)N)[C@@]2(C)[C@H]1C(O)=O QVSKBEIYSCNDSZ-VUXXRCJTSA-N 0.000 description 1
- QZVGSGRVYIQMNK-UHFFFAOYSA-N C[n]1ncc([BrH]C)c1 Chemical compound C[n]1ncc([BrH]C)c1 QZVGSGRVYIQMNK-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N Fc(cccc1)c1Br Chemical compound Fc(cccc1)c1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0055—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the 17-beta position being substituted by an uninterrupted chain of at least three carbon atoms which may or may not be branched, e.g. cholane or cholestane derivatives, optionally cyclised, e.g. 17-beta-phenyl or 17-beta-furyl derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J17/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J3/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
- C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J33/00—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J33/002—Normal steroids having a sulfur-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J9/00—Normal steroids containing carbon, hydrogen, halogen or oxygen substituted in position 17 beta by a chain of more than two carbon atoms, e.g. cholane, cholestane, coprostane
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Hospice & Palliative Care (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021090965A JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2014092369 | 2014-11-27 | ||
| CNPCT/CN2014/092369 | 2014-11-27 | ||
| PCT/CN2015/095765 WO2016082789A1 (en) | 2014-11-27 | 2015-11-27 | Compositions and methods for treating cns disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Division JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017535586A JP2017535586A (ja) | 2017-11-30 |
| JP2017535586A5 JP2017535586A5 (OSRAM) | 2019-01-10 |
| JP6893173B2 true JP6893173B2 (ja) | 2021-06-23 |
Family
ID=56073637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017528154A Active JP6893173B2 (ja) | 2014-11-27 | 2015-11-27 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021090965A Active JP7186259B2 (ja) | 2014-11-27 | 2021-05-31 | Ｃｎｓ障害を処置するための組成物および方法 |
| JP2022189056A Pending JP2023022187A (ja) | 2014-11-27 | 2022-11-28 | Ｃｎｓ障害を処置するための組成物および方法 |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US10774108B2 (OSRAM) |
| EP (2) | EP3719029A1 (OSRAM) |
| JP (3) | JP6893173B2 (OSRAM) |
| CY (1) | CY1123200T1 (OSRAM) |
| DK (1) | DK3224269T3 (OSRAM) |
| ES (1) | ES2793237T3 (OSRAM) |
| HR (1) | HRP20200840T1 (OSRAM) |
| HU (1) | HUE049014T2 (OSRAM) |
| LT (1) | LT3224269T (OSRAM) |
| ME (1) | ME03749B (OSRAM) |
| PL (1) | PL3224269T3 (OSRAM) |
| PT (1) | PT3224269T (OSRAM) |
| RS (1) | RS60343B1 (OSRAM) |
| SI (1) | SI3224269T1 (OSRAM) |
| SM (1) | SMT202000276T1 (OSRAM) |
| WO (1) | WO2016082789A1 (OSRAM) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021130698A (ja) * | 2014-11-27 | 2021-09-09 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2014169831A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| WO2014169832A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| HRP20210610T1 (hr) | 2013-07-19 | 2021-05-28 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihove uporabe |
| PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP3885352B1 (en) | 2014-10-16 | 2024-11-27 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| EP4275748A3 (en) | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| MA43284A (fr) * | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| US10435396B2 (en) * | 2016-03-03 | 2019-10-08 | Bayer Pharma Aktiegesellschaft | 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) * | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CN118271387A (zh) * | 2017-12-22 | 2024-07-02 | 萨奇治疗股份有限公司 | 治疗cns疾病的组合物和方法 |
| WO2020061332A1 (en) * | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Sterol analogs and uses thereof |
| CN109369762B (zh) * | 2018-10-31 | 2021-06-18 | 湖南玉新药业有限公司 | 17-甲酸甾族化合物的制备方法 |
| CN109503694A (zh) * | 2018-11-21 | 2019-03-22 | 苏州闻天医药科技有限公司 | 一种新型gabaa受体调节剂及其用途 |
| AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
| US10857163B1 (en) | 2019-09-30 | 2020-12-08 | Athenen Therapeutics, Inc. | Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| US12208103B1 (en) | 2021-05-07 | 2025-01-28 | Lipocine Inc. | Compositions and methods for treating CNS disorders |
| US11337987B1 (en) | 2021-05-07 | 2022-05-24 | Lipocine Inc. | Compositions and methods for treating central nervous system disorders |
Family Cites Families (151)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2856415A (en) | 1957-11-13 | 1958-10-14 | Searle & Co | 3,19-dihydroxy-5-androstene derivatives |
| FR1380417A (fr) | 1962-05-15 | 1964-12-04 | Roussel Uclaf | Nouveaux androstanyl-pyrazoles et procédé de préparation |
| US3206459A (en) | 1962-10-19 | 1965-09-14 | Syntex Corp | 10alpha-pregnan-19-ol derivatives |
| US3169134A (en) | 1963-03-21 | 1965-02-09 | Searle & Co | 2, 3-oxygenated-17alpha-methyl-5alpha-androstan-17beta-ols |
| BE754111A (fr) | 1969-07-29 | 1971-01-29 | Upjohn Co | Nouveaux 7alpha- et 7beta-methyl-3alpha,5alpha- cycloandrostanes et composes analogues 19-nor et leur procede de preparation |
| GB1434919A (en) | 1972-06-15 | 1976-05-12 | Glaxo Lab Ltd | 3alpha-hydroxy androstanes |
| GB1380246A (en) * | 1970-12-17 | 1975-01-08 | Glaxo Lab Ltd | 3alpha-hydroxy-androstanes and esters thereof |
| US3953429A (en) * | 1970-12-17 | 1976-04-27 | Glaxo Laboratories Limited | Anaesthetic steroids of the androstance and pregnane series |
| US3943124A (en) | 1970-12-17 | 1976-03-09 | Gordon Hanley Phillipps | Chemical compounds |
| GB1430942A (en) | 1972-05-05 | 1976-04-07 | Glaxo Lab Ltd | 21-substituted 3alpha-hydroxy pregnanes |
| US3983111A (en) | 1972-05-05 | 1976-09-28 | Glaxo Laboratories Limited | Steroidal anaesthetics of the pregnane and 19-norpregnane series |
| GB1436324A (en) * | 1972-05-12 | 1976-05-19 | Glaxo Lab Ltd | Anaesthetic 3alpha-hydroxy pregnanes |
| DK134348C (da) | 1973-11-30 | 1977-03-21 | Schering Ag | Analogifremgangsmade til fremstilling af d-homo-20-ketopregnaner |
| US4071625A (en) | 1974-05-13 | 1978-01-31 | Richardson-Merrell Inc. | 19-Oxygenated-5α-androstanes for the enhancement of libido |
| DE2438020A1 (de) | 1974-08-05 | 1976-02-26 | Schering Ag | 18-methyl-19-nor-20-keto-pregnane und verfahren zu ihrer herstellung |
| IL48628A0 (en) | 1974-12-23 | 1976-02-29 | Schering Ag | D-homo-20-keto-pregnanes and process for their manufactur |
| DE2526373C2 (de) | 1975-06-11 | 1983-11-10 | Schering AG, 1000 Berlin und 4709 Bergkamen | Verfahren zur Herstellung von Δ↑9↑↑(↑↑1↑↑1↑↑)↑-5α-20-Ketosteroiden |
| GB1570394A (en) | 1976-01-06 | 1980-07-02 | Glaxo Lab Ltd | 11-acyloxy-3-hydroxy steroids |
| US4192871A (en) | 1976-01-06 | 1980-03-11 | Glaxo Laboratories Limited | Chemical compounds |
| GB1581234A (en) * | 1976-04-05 | 1980-12-10 | Glaxo Operations Ltd | 11a - amino - 3a - hydroxysteroids |
| DE2632677A1 (de) | 1976-07-16 | 1978-01-26 | Schering Ag | Verfahren zur herstellung von androstan-17-on-derivaten und deren verwendung |
| GB1581235A (en) | 1977-04-04 | 1980-12-10 | Glaxo Operations Ltd | 11a-amino-3a-hydroxy-steroids |
| US4389345A (en) | 1981-10-09 | 1983-06-21 | G.D. Searle & Co. | 3-Oxoestra-17-acetonitrile and unsaturated analogs |
| US4495102A (en) | 1982-09-03 | 1985-01-22 | G. D. Searle & Co. | Aminoalkyl steroids |
| US5319115A (en) | 1987-08-25 | 1994-06-07 | Cocensys Inc. | Method for making 3α-hydroxy, 3β-substituted-pregnanes |
| US5232917A (en) | 1987-08-25 | 1993-08-03 | University Of Southern California | Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series |
| US5120723A (en) | 1987-08-25 | 1992-06-09 | University Of Southern California | Method, compositions, and compounds for modulating brain excitability |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| EP0603312A4 (en) | 1991-09-13 | 1995-06-07 | Cocensys Inc | NEW GABA A RECEPTOR WITH STEROID BINDING POINTS. |
| DE4232681C2 (de) | 1992-09-29 | 1994-11-24 | Sigma Tau Ind Farmaceuti | 17-Phenyl- und 17-Furyl-14beta,5alpha-androstan- und androsten- Derivate, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Zusammensetzung |
| JP4008024B2 (ja) | 1993-05-24 | 2007-11-14 | パーデュー、ファーマ、リミテッド、パートナーシップ | Ｇａｂａａレセプター複合体と相互作用させるための化合物 |
| EP0656365B1 (en) | 1993-12-02 | 1997-04-09 | Akzo Nobel N.V. | Substituted 2beta-morpholinoandrostane derivatives |
| CZ300694A3 (en) | 1993-12-02 | 1996-05-15 | Akzo Nobel Nv | Substituted 2beta-morpholinandrostane derivatives, process of their preparation, their use for preparing pharmaceutical preparations and pharmaceutical compositions containing thereof |
| US5939545A (en) | 1994-02-14 | 1999-08-17 | Cocensys, Inc. | Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series |
| DK1038880T3 (da) * | 1994-02-14 | 2008-03-03 | Euro Celtique Sa | Androstaner og pregnaner til allosterisk modulering af GABA-receptor |
| WO1996003421A1 (en) | 1994-07-21 | 1996-02-08 | Pharmacia & Upjohn Company | Neurologically active aminosteroids |
| GEP20002033B (en) | 1994-11-23 | 2000-04-10 | Cocensys Inc Us | Androstane and Pregnane Series Compounds for Allosteric Modulation of GABA Receptor |
| CA2223996A1 (en) | 1995-06-06 | 1996-12-19 | Cocensys, Inc. | Neuroactive steroids of the androstane and pregnane series |
| WO1998005337A1 (en) | 1996-08-01 | 1998-02-12 | Cocensys, Inc. | Use of gaba and nmda receptor ligands for the treatment of migraine headache |
| US5994334A (en) | 1997-02-05 | 1999-11-30 | University Of Maryland | Androgen synthesis inhibitors |
| US5935545A (en) | 1997-07-11 | 1999-08-10 | E. I. Du Pont De Nemours And Company | Process for producing an aqueous solution comprising ferric chloride |
| WO1999045931A1 (en) | 1998-03-11 | 1999-09-16 | Baeckstroem Torbjoern | Epiallopregnanolone in the treatment of cns disorders |
| HUP0201818A3 (en) | 1999-04-29 | 2004-04-28 | Euro Celtique Sa | 3alpha-hydroxy-3beta-methoxymethyl-21-heterocycle substituted steroids with anesthetic activity and pharmaceutical compositions containing the same |
| US7018406B2 (en) | 1999-11-17 | 2006-03-28 | Corevalve Sa | Prosthetic valve for transluminal delivery |
| ATE297406T1 (de) | 2000-02-18 | 2005-06-15 | Taiho Pharmaceutical Co Ltd | Verfahren zur herstellung von steroid-derivaten |
| US6855836B2 (en) | 2000-10-26 | 2005-02-15 | Jenapharm Gmbh & Co. Kg | 17-Methylene steroids, process for their production and pharmaceutical compositions that contain these compounds |
| EP1330467B1 (en) | 2000-11-03 | 2007-05-02 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| GR1003861B (el) | 2000-12-29 | 2002-04-11 | Νεα νευροστεροειδη που αλληλεπιδρουν με τον υποδοχεα gabaa. | |
| AU2004224053B2 (en) | 2003-03-24 | 2011-06-09 | Sterix Limited | Oestrogen derivatives as inhibitors of steroid sulphatase |
| US7781421B2 (en) | 2003-05-29 | 2010-08-24 | Washington University | Neuroactive 13, 24-cyclo-18, 21-dinorcholanes and structurally related pentacyclic steriods |
| JP2007512344A (ja) | 2003-11-24 | 2007-05-17 | メルク エンド カムパニー インコーポレーテッド | エストロゲン受容体調節剤 |
| US20090118248A1 (en) | 2004-04-23 | 2009-05-07 | Euro-Celtique S.A. | 3-Alpha-hydroxy 21-n-heteroaryl-pregnane derivatives for modulation of brain excitability and a process for the production thereof |
| WO2006037016A2 (en) * | 2004-09-27 | 2006-04-06 | The Regents Of The University Of California | Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury |
| EP2471536A1 (en) | 2004-09-29 | 2012-07-04 | Harbor BioSciences, Inc. | Steroid analogs and characterization and treatment methods |
| DE602006013622D1 (de) | 2005-06-09 | 2010-05-27 | Euro Celtique Sa | Steroids und anwendungen davon |
| ES2662500T3 (es) | 2006-11-21 | 2018-04-06 | Asarina Pharma Ab | El uso de esteroides de pregnano y androstano para la preparación de una composición farmacéutica para el tratamiento de trastornos del sistema nervioso central |
| US20090203658A1 (en) | 2007-01-08 | 2009-08-13 | Duke University | Neuroactive steroid compositions and methods of use therefor |
| DE102007027636A1 (de) | 2007-06-12 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | 17ß-Cyano-18a-homo-19-nor-androst-4-en-Derivat, dessen Verwendung und das Derivat enthaltende Arzneimittel |
| CA2698172C (en) | 2007-06-15 | 2014-02-18 | Cook, Kevin M. | Androstane and pregnane steroids with potent allosteric gaba receptor chloride ionophore modulating properties |
| GB0711948D0 (en) | 2007-06-20 | 2007-08-01 | Bionature E A Ltd | Neurosteriod compounds |
| CN101412742B (zh) | 2007-10-19 | 2013-07-31 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| US20090264443A1 (en) | 2008-04-18 | 2009-10-22 | David Helton | Treatment of organophosphate exposure with tetrahydroindolone arylpiperazine compounds |
| CN101624414B (zh) | 2008-07-07 | 2013-02-13 | 天津金耀集团有限公司 | 一种抑制血管新生的硝酸酯药物 |
| CZ301216B6 (cs) | 2008-07-10 | 2009-12-09 | Ústav organické chemie a biochemie Akademie ved CR, v. v. i. | Pregnanové anionické slouceniny, zpusob jejich výroby a jejich použití |
| WO2010054158A2 (en) | 2008-11-07 | 2010-05-14 | Auspex Pharmaceuticals, Inc. | Steroid modulators of glucocorticoid receptor |
| US20110152840A1 (en) | 2009-12-23 | 2011-06-23 | Drugtech Corporation | Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions |
| EP2598513A1 (en) | 2010-07-30 | 2013-06-05 | Medexis S.A. | Compounds and methods for treating neoplasia |
| EP2667876A2 (en) | 2010-12-15 | 2013-12-04 | Harbor BioSciences, Inc. | Methods and compounds for preparing 3alpha-oxygen substituted steroids |
| CA2828047C (en) | 2011-02-15 | 2020-03-10 | Socpra Sciences Et Genie, S.E.C. | Steroid alkaloids and uses thereof as antimicrobial agents against electron transport-deficient microbes and as potentiators for antimicrobial agents against pathogenic bacteria |
| CZ303443B6 (cs) | 2011-02-15 | 2012-09-12 | Ústav organické chemie a biochemie Akademie ved CR, v.v.i. | Deriváty pregnanolonu substituované v poloze 3alfa kationickou skupinou, zpusob jejich výroby, jejich použití a prostredek je obsahující |
| US9388210B2 (en) | 2011-02-25 | 2016-07-12 | Washington University | Neuroactive 17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9851309B2 (en) | 2011-03-23 | 2017-12-26 | Satoshi Watabe | Ultra-high-sensitive assay of protein and nucleic acid and kit, and novel enzyme substrate |
| CA2843436A1 (en) | 2011-07-29 | 2013-02-07 | The Regents Of The University Of California | Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| WO2013036835A1 (en) | 2011-09-08 | 2013-03-14 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| CN113234114A (zh) | 2011-10-14 | 2021-08-10 | 萨奇治疗股份有限公司 | 3,3-二取代的19-去甲孕甾烷化合物、组合物、及其用途 |
| CA2862076C (en) | 2012-01-23 | 2020-04-21 | Sage Therapeutics, Inc. | Neuroactive steroid formulations and methods of treating cns disorders |
| WO2013188792A2 (en) | 2012-06-15 | 2013-12-19 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| ES2822375T3 (es) | 2012-06-19 | 2021-04-30 | Intercept Pharmaceuticals Inc | Preparación de la forma no cristalina del ácido obeticólico |
| WO2014028398A2 (en) | 2012-08-13 | 2014-02-20 | The Regents Of The University Of California | Mitigation of epileptic seizures by combination therapy using benzodiazepines and neurosteroids |
| PL2887944T3 (pl) | 2012-08-21 | 2022-02-21 | Sage Therapeutics, Inc. | Allopregnanolon do leczenia lekoopornego stanu padaczkowego |
| US9765110B2 (en) | 2012-10-08 | 2017-09-19 | Washington University | Neuroactive 19-alkoxy-17(20)-Z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US9757391B2 (en) * | 2012-11-09 | 2017-09-12 | Goodchild Investments Pty Ltd | Neuroactive steroids and their use to facilitate neuroprotection |
| JP2016501876A (ja) | 2012-11-30 | 2016-01-21 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ステロイドの抗痙攣活性 |
| SG10201706063UA (en) | 2012-12-18 | 2017-09-28 | Univ Washington | Neuroactive 19-alkoxy-17-substituted steroids, prodrugs thereof, and methods of treatment using same |
| US8939545B2 (en) | 2012-12-20 | 2015-01-27 | Eastman Kodak Company | Inkjet printing with managed airflow for condensation control |
| WO2014108808A2 (en) | 2013-01-09 | 2014-07-17 | Henry James Lorne | Pharmaceutical formulations for the treatment and prevention of trauma-induced neuropathology and neurodegeneration |
| CA2831054C (en) | 2013-01-09 | 2016-08-30 | Sapna Life Sciences Corp. | Formulations, and methods for their use in treatment of neuropathology and neurodegeneration as a result of traumatic injury |
| GB201302368D0 (en) | 2013-02-11 | 2013-03-27 | Univ Bath | Compound |
| US9512170B2 (en) | 2013-03-01 | 2016-12-06 | Washington University | Neuroactive 13, 17-substituted steroids as modulators for GABA type-A receptors |
| US9562026B2 (en) | 2013-03-14 | 2017-02-07 | Washington University | Neuroactive substituted cyclopent[a]anthracenes as modulators for GABA type-A receptors |
| WO2014169831A1 (en) * | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor c3,3-disubstituted c21-c-bound heteroaryl steroids and methods of use thereof |
| MX362543B (es) | 2013-04-17 | 2019-01-24 | Sage Therapeutics Inc | Esteroides c21-n-pirazolilo 19-nor c3,3- disustituidos y metodos de uso de los mismos. |
| WO2014169832A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| WO2014169836A1 (en) | 2013-04-17 | 2014-10-23 | Sage Therapeutics, Inc. | 19-nor neuroactive steroids and methods of use thereof |
| HRP20210610T1 (hr) | 2013-07-19 | 2021-05-28 | Sage Therapeutics, Inc. | Neuroaktivni steroidi, pripravci i njihove uporabe |
| PT3035940T (pt) | 2013-08-23 | 2019-01-28 | Sage Therapeutics Inc | Esteroides neuroativos, composições e seus usos |
| SG10201803812TA (en) | 2014-05-29 | 2018-06-28 | Sage Therapeutics Inc | Neuroactive steroids, compositions, and uses thereof |
| WO2015195962A1 (en) | 2014-06-18 | 2015-12-23 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| US10172870B2 (en) | 2014-09-02 | 2019-01-08 | The Texas A&M University System | Method of treating organophosphate intoxication by administration of neurosteroids |
| JOP20200195A1 (ar) | 2014-09-08 | 2017-06-16 | Sage Therapeutics Inc | سترويدات وتركيبات نشطة عصبياً، واستخداماتها |
| EP4275748A3 (en) | 2014-10-16 | 2024-01-03 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| EP3885352B1 (en) | 2014-10-16 | 2024-11-27 | Sage Therapeutics, Inc. | A compound, compositions thereof and this compound for use in methods of treating cns disorders |
| RS60343B1 (sr) | 2014-11-27 | 2020-07-31 | Sage Therapeutics Inc | Kompozicije i postupci za lečenje poremećaja cns-a |
| SMT202100113T1 (it) | 2015-01-26 | 2021-05-07 | Sage Therapeutics Inc | Composizioni e metodi per trattare disturbi del snc |
| CN105985396A (zh) | 2015-02-16 | 2016-10-05 | 苏州泽璟生物制药有限公司 | 氘代鹅去氧胆酸衍生物以及包含该化合物的药物组合物 |
| EP3258939B1 (en) | 2015-02-20 | 2022-09-07 | Sage Therapeutics, Inc. | Neuroactive steroids, compositions, and uses thereof |
| EP3280420B1 (en) | 2015-04-10 | 2024-03-27 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| MA45276A (fr) | 2015-06-18 | 2018-04-25 | Sage Therapeutics Inc | Solutions de stéroïdes neuroactifs et leurs méthodes d'utilisation |
| UY36741A (es) | 2015-06-21 | 2016-12-30 | Prevacus Inc | Compuesto de esteroide c-20, sus composiciones y usos para tratar la lesión cerebral traumática (tbi), que incluye las conmociones cerebrales |
| WO2017044659A1 (en) | 2015-09-08 | 2017-03-16 | Viewpoint Therapeutics, Inc. | Compounds and formulations for treating ophthalmic diseases |
| CA3001722A1 (en) | 2015-10-16 | 2017-04-20 | Marinus Pharmaceuticals, Inc. | Injectable neurosteroid formulations containing nanoparticles |
| MA43284A (fr) | 2015-11-20 | 2018-09-26 | Sage Therapeutics Inc | Composés et leurs méthodes d'utilisation |
| CN113616661A (zh) | 2016-03-08 | 2021-11-09 | 萨奇治疗股份有限公司 | 神经活性类固醇、其组合物及用途 |
| US10226550B2 (en) | 2016-03-11 | 2019-03-12 | Brigham Young University | Cationic steroidal antimicrobial compositions for the treatment of dermal tissue |
| AU2017296295B2 (en) | 2016-07-11 | 2022-02-24 | Sage Therapeutics, Inc. | C7, C12, and C16 substituted neuroactive steroids and their methods of use |
| MA45599A (fr) | 2016-07-11 | 2019-05-15 | Sage Therapeutics Inc | Stéroïdes neuroactifs substitués en c17, c20 et c21 et leurs procédés d'utilisation |
| JOP20190022B1 (ar) | 2016-08-23 | 2023-03-28 | Sage Therapeutics Inc | ستيرويد 19- نور c3، 3- به استبدال ثنائي لـ c21-n بيرازوليل بلوري |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| CN108727453A (zh) | 2017-04-20 | 2018-11-02 | 华东理工大学 | 新型pd-1抑制剂及其应用 |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| US11285139B2 (en) | 2017-08-31 | 2022-03-29 | Takeda Pharmaceutical Company Limited | Treatment of CNS conditions |
| EP3678670A1 (en) | 2017-09-07 | 2020-07-15 | Sage Therapeutics, Inc. | Neuroactive steroids and their methods of use |
| US20200276209A1 (en) | 2017-09-11 | 2020-09-03 | Sage Therapeutics, Inc. | Methods of treating epilepsy or status epilepticus |
| AU2018334214A1 (en) | 2017-09-14 | 2020-03-26 | Sage Therapeutics, Inc. | A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof |
| WO2019094724A1 (en) | 2017-11-10 | 2019-05-16 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating genetic epileptic disoders |
| US20200291059A1 (en) | 2017-12-08 | 2020-09-17 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| AU2018392093B2 (en) | 2017-12-22 | 2024-02-01 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| CN118271387A (zh) | 2017-12-22 | 2024-07-02 | 萨奇治疗股份有限公司 | 治疗cns疾病的组合物和方法 |
| US11718642B2 (en) | 2018-01-12 | 2023-08-08 | Sage Therapeutics, Inc. | Compositions and methods for treating CNS disorders |
| CN117959309A (zh) | 2018-06-12 | 2024-05-03 | 萨奇治疗股份有限公司 | 19-去甲基c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| EP4321519A3 (en) | 2018-10-12 | 2024-05-01 | Sage Therapeutics, Inc. | Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of cns disorders |
| MX2021004452A (es) | 2018-10-19 | 2021-08-11 | Sage Therapeutics Inc | Esteroides neuroactivos no saturados 9(11) y sus métodos de uso. |
| TW202521129A (zh) | 2018-12-05 | 2025-06-01 | 美商賽吉醫療公司 | 神經活性類固醇及其使用方法 |
| US20220372067A1 (en) | 2018-12-21 | 2022-11-24 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof |
| TW202523658A (zh) | 2019-05-24 | 2025-06-16 | 美商賽吉醫療公司 | 化合物、組合物及使用方法 |
| AR119047A1 (es) | 2019-05-31 | 2021-11-17 | Sage Therapeutics Inc | Esteroides neuroactivos como moduladores de gabaa y su uso en el tratamiento de trastornos del snc |
| US20230303616A9 (en) | 2019-06-27 | 2023-09-28 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| CA3143545A1 (en) | 2019-06-27 | 2020-12-30 | Sage Therapeutics, Inc. | Compounds for treating cns disorders |
| CN114787174A (zh) | 2019-06-27 | 2022-07-22 | 萨奇治疗股份有限公司 | 用于治疗cns病症的组合物和方法 |
| CN114761019A (zh) | 2019-12-05 | 2022-07-15 | 萨奇治疗股份有限公司 | 19-去甲c3,3-二取代的c21-n-吡唑基类固醇及其使用方法 |
| JP2023518411A (ja) | 2020-03-18 | 2023-05-01 | セージ セラピューティクス， インコーポレイテッド | 神経刺激性ステロイド及びその使用方法 |
| EP4125921A1 (en) | 2020-03-25 | 2023-02-08 | Sage Therapeutics, Inc. | Use of agents for treatment of respiratory conditions |
| WO2021262836A1 (en) | 2020-06-24 | 2021-12-30 | Sage Therapeutics, Inc. | 3.alpha.-hydroxy, 17.beta.-c(o)-n-aryl substituted neuroactive steroids and compositions thereof |
| AR123018A1 (es) | 2020-07-20 | 2022-10-26 | Sage Therapeutics Inc | Formulaciones del esteroide c21-n-pirazolilo 19-nor c3,3-disustituido y métodos de uso de este |
| AU2021385335A1 (en) | 2020-11-25 | 2023-06-29 | Sage Therapeutics, Inc. | Compositions and methods for treating cns disorders |
| WO2022165017A1 (en) | 2021-01-28 | 2022-08-04 | Sage Therapeutics, Inc. | Use of neuroactive steroids for treatment of sexual dysfunction |
| US20240148756A1 (en) | 2021-02-18 | 2024-05-09 | Sage Therapeutics, Inc. | Use of neuroactive steroid for treatment of sexual dysfunction |
| BR112023018607A2 (pt) | 2021-03-17 | 2023-10-24 | Sage Therapeutics Inc | Esteroide de c21-n-pirazolil 19-nor c3,3-dissubstituído para o tratamento de transtorno depressivo maior |
| AU2022258203A1 (en) | 2021-04-12 | 2023-10-26 | Sage Therapeutics, Inc. | Treatment of essential tremor |
| CA3217866A1 (en) | 2021-04-29 | 2022-11-03 | Sage Therapeutics, Inc. | Neuroactive steroid for use in treating major depressive disorder and postpartum depression in a lactating female |
| IL307991A (en) | 2021-04-29 | 2023-12-01 | Sage Therapeutics Inc | 19-NOR C3, 3- di-converted C21-N-pyrazolyl steroid for use in the treatment of major depressive disorder and postpartum depression |
-
2015
- 2015-11-27 RS RS20200610A patent/RS60343B1/sr unknown
- 2015-11-27 ME MEP-2020-105A patent/ME03749B/me unknown
- 2015-11-27 ES ES15862506T patent/ES2793237T3/es active Active
- 2015-11-27 DK DK15862506.1T patent/DK3224269T3/da active
- 2015-11-27 SM SM20200276T patent/SMT202000276T1/it unknown
- 2015-11-27 EP EP20159317.5A patent/EP3719029A1/en not_active Ceased
- 2015-11-27 EP EP15862506.1A patent/EP3224269B1/en active Active
- 2015-11-27 HR HRP20200840TT patent/HRP20200840T1/hr unknown
- 2015-11-27 LT LTEP15862506.1T patent/LT3224269T/lt unknown
- 2015-11-27 SI SI201531219T patent/SI3224269T1/sl unknown
- 2015-11-27 PT PT158625061T patent/PT3224269T/pt unknown
- 2015-11-27 JP JP2017528154A patent/JP6893173B2/ja active Active
- 2015-11-27 US US15/531,313 patent/US10774108B2/en active Active
- 2015-11-27 WO PCT/CN2015/095765 patent/WO2016082789A1/en not_active Ceased
- 2015-11-27 PL PL15862506T patent/PL3224269T3/pl unknown
- 2015-11-27 HU HUE15862506A patent/HUE049014T2/hu unknown
-
2020
- 2020-02-25 US US16/800,053 patent/US20210017218A1/en not_active Abandoned
- 2020-05-26 CY CY20201100480T patent/CY1123200T1/el unknown
-
2021
- 2021-05-31 JP JP2021090965A patent/JP7186259B2/ja active Active
-
2022
- 2022-10-04 US US17/959,592 patent/US11945836B2/en active Active
- 2022-11-28 JP JP2022189056A patent/JP2023022187A/ja active Pending
-
2024
- 2024-02-20 US US18/581,595 patent/US20250042934A1/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021130698A (ja) * | 2014-11-27 | 2021-09-09 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
| JP7186259B2 (ja) | 2014-11-27 | 2022-12-08 | セージ セラピューティクス， インコーポレイテッド | Ｃｎｓ障害を処置するための組成物および方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| ME03749B (me) | 2021-04-20 |
| SMT202000276T1 (it) | 2020-07-08 |
| HRP20200840T1 (hr) | 2020-11-13 |
| HUE049014T2 (hu) | 2020-09-28 |
| JP2017535586A (ja) | 2017-11-30 |
| JP7186259B2 (ja) | 2022-12-08 |
| US20170342102A1 (en) | 2017-11-30 |
| LT3224269T (lt) | 2020-07-10 |
| US20250042934A1 (en) | 2025-02-06 |
| RS60343B1 (sr) | 2020-07-31 |
| PL3224269T3 (pl) | 2020-08-24 |
| PT3224269T (pt) | 2020-06-01 |
| JP2021130698A (ja) | 2021-09-09 |
| EP3224269B1 (en) | 2020-02-26 |
| EP3719029A1 (en) | 2020-10-07 |
| CY1123200T1 (el) | 2021-10-29 |
| DK3224269T3 (da) | 2020-05-25 |
| US20230279043A1 (en) | 2023-09-07 |
| EP3224269A1 (en) | 2017-10-04 |
| ES2793237T3 (es) | 2020-11-13 |
| US20210017218A1 (en) | 2021-01-21 |
| JP2023022187A (ja) | 2023-02-14 |
| EP3224269A4 (en) | 2018-07-25 |
| SI3224269T1 (sl) | 2020-10-30 |
| WO2016082789A1 (en) | 2016-06-02 |
| US10774108B2 (en) | 2020-09-15 |
| US11945836B2 (en) | 2024-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6893173B2 (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| AU2022203444B2 (en) | Compositions and methods for treating CNS disorders | |
| JP6826615B2 (ja) | 向神経活性ステロイド、組成物、及びその使用 | |
| JP7012119B2 (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| JP7049313B2 (ja) | Ｃ１７、ｃ２０、およびｃ２１置換神経刺激性ステロイドおよびそれらの使用方法 | |
| JP6875996B2 (ja) | 神経刺激性ステロイド、組成物、およびその使用 | |
| JP2020189848A (ja) | Ｃｎｓ障害を処置するための組成物および方法 | |
| KR20210107050A (ko) | 3.알파.-히드록시-17.베타.-아미드 신경활성 스테로이드 및 그의 조성물 | |
| HK1236539B (en) | Compositions and methods for treating cns disorders | |
| HK1236539A1 (en) | Compositions and methods for treating cns disorders | |
| BR112019000578B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas e seus usos | |
| BR122022005124B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits | |
| BR122022005119B1 (pt) | Compostos esteróides neuroativos c17, c20 e c21 substituídos, suas composições farmacêuticas, seus usos e kits |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20181126 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20181126 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20191217 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200316 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200413 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200924 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201223 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210315 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210331 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210430 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210531 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6893173 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |